anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Acetylcysteine
Trial phase: Phase 2
ATC code: R05CB01 | S01XA08 | V03AB23
SMILES: CC(=O)N[C@@H](CS)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 16
Group description: Patients receive acetylcysteine oral rinse and gargle or swish for 60 seconds then spit 5 times per day beginning within 3 days of the initiation of radiotherapy to 14 days following completion of radiotherapy.
Eligibility criteria:
Inclusion Criteria:

Histological confirmation of tumor of the oral cavity, oropharynx, supraglottic larynx, or nasopharynx
Receiving concurrent chemoradiotherapy/chemobiotherapy to a minimum dose equivalent to 60 Gy in 30 fractions in the adjuvant or definitive setting
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
Initiation of investigational agent =< 3 days after initiation of radiotherapy
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Ability to complete questionnaire(s) by themselves or with assistance
Provide informed written consent
Willing to return mail-in questionnaires during the observation phase of the study

Exclusion Criteria:

Any of the following:

Pregnant women
Nursing women
Men or women of childbearing potential who are unwilling to employ adequate contraception
Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
History of myocardial infarction =< 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
Receipt of induction chemotherapy
Previous receipt of head and neck irradiation
Utilization of amifostine during radiotherapy
Greater than or equal to grade 2 dry mouth prior to chemoradiotherapy or greater than or equal to grade 2 mucositis
Previous intolerance/adverse effect/allergy to any component of the placebo or active agent
History of Sjogren's, lupus or scleroderma
Intervention: Minocycline
Trial phase: Phase 4
ATC code: A01AB23 | D10AF07 | J01AA08 | J01AA20
SMILES: [H][C@@]12Cc3c(N(C)C)ccc(O)c3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Participants with treatment resistant schizophrenia and a high baseline C-reactive protein (CRP) level received minocycline augmentation with clozapine. CRP levels were measured by a high sensitivity CRP test (hs-CRP) and baseline values greater than 3 milligrams per liter (mg/L) of blood are considered high.
Eligibility criteria:
Inclusion Criteria:

Mini International Neuropsychiatric Interview 6.0 diagnosis of schizophrenia or schizoaffective disorder
Persistent symptoms of schizophrenia as measured by one of the following PANSS items: Total score ≥60, negative subscale ≥ 15, positive subscale ≥ 15, general psychopathology subscale ≥ 30
Currently taking clozapine and the dose has been adjusted within 100 mg of study enrollment
Currently taking clozapine for 3 months and documented clozapine level ≥ 350 ng/ml prior to study start
No other psychotropic medication changes for one month prior to study enrollment
No new psychosocial interventions for one month prior to study enrollment
No prior experience on minocycline for greater than 1 week
May be taking any other psychotropic, dermatologic, or gastrointestinal drugs

Exclusion Criteria:

History of organic brain disease
Diagnostic and Statistical Manual of Mental Disorders (DSM) IV-TR diagnosis of Mental Retardation or Dementia
DSM-IV-TR diagnosis of Alcohol or Substance Dependence within the last six months (except nicotine)
Pregnancy or lactation
Known hypersensitivity to tetracyclines
Current known infection
Any known neurological disease or medical condition that could impact the measurement of the constructs being assessed
Inpatient psychiatric hospitalization for worsening of psychiatric symptoms, OR worsening of symptoms requiring a new level of outpatient support, OR started on a new anti-inflammatory medication for greater than one week duration, OR addition of a new psychotropic medication for psychiatric symptom control
A change in > 15% in PANSS score from the "Lead-In Visit" to the "M0 visit"
Intervention: Minocycline
Trial phase: Phase 4
ATC code: A01AB23 | D10AF07 | J01AA08 | J01AA20
SMILES: [H][C@@]12Cc3c(N(C)C)ccc(O)c3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Participants with treatment resistant schizophrenia and a low baseline C-reactive protein (CRP) level received minocycline augmentation with clozapine. CRP levels were measured by a high sensitivity CRP test (hs-CRP) and baseline values equal to or less than 3 milligrams per liter (mg/L) of blood are considered low.
Eligibility criteria:
Inclusion Criteria:

Mini International Neuropsychiatric Interview 6.0 diagnosis of schizophrenia or schizoaffective disorder
Persistent symptoms of schizophrenia as measured by one of the following PANSS items: Total score ≥60, negative subscale ≥ 15, positive subscale ≥ 15, general psychopathology subscale ≥ 30
Currently taking clozapine and the dose has been adjusted within 100 mg of study enrollment
Currently taking clozapine for 3 months and documented clozapine level ≥ 350 ng/ml prior to study start
No other psychotropic medication changes for one month prior to study enrollment
No new psychosocial interventions for one month prior to study enrollment
No prior experience on minocycline for greater than 1 week
May be taking any other psychotropic, dermatologic, or gastrointestinal drugs

Exclusion Criteria:

History of organic brain disease
Diagnostic and Statistical Manual of Mental Disorders (DSM) IV-TR diagnosis of Mental Retardation or Dementia
DSM-IV-TR diagnosis of Alcohol or Substance Dependence within the last six months (except nicotine)
Pregnancy or lactation
Known hypersensitivity to tetracyclines
Current known infection
Any known neurological disease or medical condition that could impact the measurement of the constructs being assessed
Inpatient psychiatric hospitalization for worsening of psychiatric symptoms, OR worsening of symptoms requiring a new level of outpatient support, OR started on a new anti-inflammatory medication for greater than one week duration, OR addition of a new psychotropic medication for psychiatric symptom control
A change in > 15% in PANSS score from the "Lead-In Visit" to the "M0 visit"
Intervention: BQ-123
Trial phase: Early Phase 1
SMILES: CC(C)C[C@@H]1NC(=O)[C@@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 30
Group description: Control

BQ-123: Endothelin subtype A antagonist
Eligibility criteria:
Inclusion Criteria:

General Inclusion/Exclusion Criteria:

The study group will include subjects with a history of stable cardiomyopathy (ischemic and non-ischemic, >3 months duration, ages 45-75 yrs) despite a minimum of 6 weeks of optimal treatment.
Optimal therapy will be according to AHA/ACC and HFSA HF guidelines, including treatment with ACE and -blocker therapy (for at least 6 weeks), or have documented reason for variation, including medication intolerance, contraindication, patient preference, or personal physician's judgment.
Patient enrollment will be limited to those individuals with NYHA class II and III symptoms, LVEF<35%, with no or minimal smoking history (<15 pk yrs), and without pacemakers.

Exclusion Criteria:

Patients with atrial fibrillation or HF believed to be secondary to atrial fibrillation will be excluded.
Patients with HF secondary to significant uncorrected primary valvular disease (except mitral regurgitation secondary to left ventricular dysfunction) will also be excluded.
Patients will be sedentary, defined here as no regular physical activity for at least the prior 6 months and current activity level will be documented by an activity questionnaire.
Patients must have no orthopedic limitations that would prohibit them from performing knee-extensor exercise.
Due to the typical age of patients with HF, all women will be postmenopausal (either natural or surgical) defined as a cessation of menses for at least 2 years, and in women without a uterus, follicle stimulating hormone (FSH) >40 IU/L.

Women currently taking hormone replacement therapy (HRT) will be excluded from the proposed studies due to the direct vascular effects of HRT Comorbidity Exclusion Criteria: Patients with significant non-cardiac comorbidities, which if present could alter the study results, will be excluded.

These include a diagnosis of Dementia
Severe COPD
Peripheral Vascular Disease
Anemia
Sleep-related Breathing Disorder
Severe Valvular Heart Disease
Diabetes (if on insulin therapy)
or End-stage Malignancy
The investigators will also exclude morbidly obese patients (BMI >35), patients with uncontrolled Hypertension (>160/100), Anemia (Hgb<9) and Severe Renal Insufficiency (individuals with creatinine clearance <30 by the Cockcroft-Gault formula).
Intervention: BQ-123
Trial phase: Early Phase 1
SMILES: CC(C)C[C@@H]1NC(=O)[C@@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 30
Group description: Heart Failure

BQ-123: Endothelin subtype A antagonist
Eligibility criteria:
Inclusion Criteria:

General Inclusion/Exclusion Criteria:

The study group will include subjects with a history of stable cardiomyopathy (ischemic and non-ischemic, >3 months duration, ages 45-75 yrs) despite a minimum of 6 weeks of optimal treatment.
Optimal therapy will be according to AHA/ACC and HFSA HF guidelines, including treatment with ACE and -blocker therapy (for at least 6 weeks), or have documented reason for variation, including medication intolerance, contraindication, patient preference, or personal physician's judgment.
Patient enrollment will be limited to those individuals with NYHA class II and III symptoms, LVEF<35%, with no or minimal smoking history (<15 pk yrs), and without pacemakers.

Exclusion Criteria:

Patients with atrial fibrillation or HF believed to be secondary to atrial fibrillation will be excluded.
Patients with HF secondary to significant uncorrected primary valvular disease (except mitral regurgitation secondary to left ventricular dysfunction) will also be excluded.
Patients will be sedentary, defined here as no regular physical activity for at least the prior 6 months and current activity level will be documented by an activity questionnaire.
Patients must have no orthopedic limitations that would prohibit them from performing knee-extensor exercise.
Due to the typical age of patients with HF, all women will be postmenopausal (either natural or surgical) defined as a cessation of menses for at least 2 years, and in women without a uterus, follicle stimulating hormone (FSH) >40 IU/L.

Women currently taking hormone replacement therapy (HRT) will be excluded from the proposed studies due to the direct vascular effects of HRT Comorbidity Exclusion Criteria: Patients with significant non-cardiac comorbidities, which if present could alter the study results, will be excluded.

These include a diagnosis of Dementia
Severe COPD
Peripheral Vascular Disease
Anemia
Sleep-related Breathing Disorder
Severe Valvular Heart Disease
Diabetes (if on insulin therapy)
or End-stage Malignancy
The investigators will also exclude morbidly obese patients (BMI >35), patients with uncontrolled Hypertension (>160/100), Anemia (Hgb<9) and Severe Renal Insufficiency (individuals with creatinine clearance <30 by the Cockcroft-Gault formula).
Intervention: Calcitriol
Trial phase: Phase 4
ATC code: A11CC04 | D05AX03
SMILES: [H][C@@]12CC[C@]([H])([C@H](C)CCCC(C)(C)O)[C@@]1(C)CCC/C2=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 54
Group description: Participants received calcitriol 3 mcg/g ointment twice daily without exceeding a maximum of 0.5 g/kg of body weight or 28 g daily (whichever was the lower) up to 26 weeks. Participants were further followed up for 4 weeks.
Eligibility criteria:
Inclusion Criteria:

Male or female 2 to 16 years and 11 months of age
Clinical diagnosis of stable mild to moderate plaque psoriasis

Exclusion Criteria:

Other forms of psoriasis
Hypercalcemia
Past history of kidney stones
Vitamin D deficiency
Other concomitant dermatological disease
Intervention: MESALAMINE
Trial phase: Phase 1
ATC code: A07EC02
SMILES: Nc1ccc(O)c(C(=O)O)c1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 18
Group description: One 500mg Mesalamine capsule opened and the contents sprinkled onto 1 tablespoon of commercially available low-fat vanilla yogurt. All 3 treatments were administered on the same day, with a 2-hour washout period between investigational product administrations in each treatment period.
Eligibility criteria:
Inclusion Criteria:

normal, healthy, adult male and female volunteers, without evidence of active or chronic disease
Intervention: MESALAMINE
Trial phase: Phase 1
ATC code: A07EC02
SMILES: Nc1ccc(O)c(C(=O)O)c1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 18
Group description: One 500mg Mesalamine capsule opened and the contents sprinkled onto 1 tablespoon of commercially available unsweetened, creamy applesauce. All 3 treatments were administered on the same day, with a 2-hour washout period between investigational product administrations in each treatment period.
Eligibility criteria:
Inclusion Criteria:

normal, healthy, adult male and female volunteers, without evidence of active or chronic disease
Intervention: MESALAMINE
Trial phase: Phase 1
ATC code: A07EC02
SMILES: Nc1ccc(O)c(C(=O)O)c1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 18
Group description: One 500mg Mesalamine capsule opened and the contents emptied into a dosing cup; contents were then administered to the subject with 240ml of water. All 3 treatments were administered on the same day, with a 2-hour washout period between investigational product administrations in each treatment period.
Eligibility criteria:
Inclusion Criteria:

normal, healthy, adult male and female volunteers, without evidence of active or chronic disease
Intervention: Kenalog
Trial phase: Not Applicable
SMILES: CC1(C)OC2CC3C4CCC5=CC(=O)C=CC5(C)C4(F)C(O)CC3(C)C2(C(=O)CO)O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 120
Group description: 40mg/ 2ml with local anesthetic

Kenalog
Eligibility criteria:
Inclusion Criteria:

Clinical diagnosis of trochanteric bursitis
18 years of age or older when written informed consent is obtained
Signed institutional review board approved informed consent form

Exclusion Criteria:

Meets any contraindication for treatment
Allergy to triamcinolone, lidocaine
Previous surgery to bursa
Coagulopathy
Active Infection
Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or complete study assessments
Intervention: Kenalog
Trial phase: Not Applicable
SMILES: CC1(C)OC2CC3C4CCC5=CC(=O)C=CC5(C)C4(F)C(O)CC3(C)C2(C(=O)CO)O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 120
Group description: 80mg/ 2ml and local anesthetic

Kenalog
Eligibility criteria:
Inclusion Criteria:

Clinical diagnosis of trochanteric bursitis
18 years of age or older when written informed consent is obtained
Signed institutional review board approved informed consent form

Exclusion Criteria:

Meets any contraindication for treatment
Allergy to triamcinolone, lidocaine
Previous surgery to bursa
Coagulopathy
Active Infection
Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or complete study assessments
Intervention: OXYTOCIN
Trial phase: Phase 2
ATC code: H01BB02
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 8
Group description: Subjects would receive 4 IU of intranasal oxytocin; one spray in each nostril, single-use.

Intranasal Oxytocin: Intranasal spray, one spray or 4 IU of oxytocin will be administered into each nostril of each patient about 15-30 minutes before NAF collection
Eligibility criteria:
Inclusion Criteria:

Clinical diagnosis of Ductal carcinoma in situ (DCIS) or invasive breast cancer
Candidate for breast conserving surgery or mastectomy

Exclusion Criteria:

Pregnant women
Prior Breast Cancer diagnosis
Adverse reaction to Oxytocin in the past
Intervention: Ferric citrate
Trial phase: Phase 2
ATC code: V03AE08
SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Fe+3]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 32
Group description: KRX-0502 (ferric citrate)

KRX-0502: 1g tablets of KRX-0502
Eligibility criteria:
Inclusion Criteria:

Males and non-lactating females with negative serum pregnancy test (for females of child-bearing potential) at Screening
Age ≥ 18 years
Serum ferritin ≤ 300 ng/mL and TSAT ≤ 25% at Screening
Hemoglobin ≥9.0 g/dL and ≤11.5 g/dL at Screening
eGFR <60 mL/min at Screening using the 4-variable Modification of Diet in Renal Disease (MDRD) equation

Exclusion Criteria:

Subjects receiving phosphate binder medication(s) at, or within 4 weeks prior to, screening
Symptomatic gastrointestinal bleeding, inflammatory bowel disease, inflammatory bowel syndrome and/or Crohn's Disease within 24 weeks prior to \ Screening
Evidence of acute kidney injury or requirement for dialysis within 8 weeks prior to Screening
Kidney transplant anticipated or start of dialysis expected within 16 weeks of Screening
History of hemochromatosis
IV iron administered within 4 weeks prior to Screening
Erythropoiesis-Stimulating Agent (ESA) administered within 4 weeks prior to Screening
Blood transfusion within 4 weeks prior to Screening
Receipt of any investigational drug within 4 weeks prior to Screening
Cause of anemia other than iron deficiency or chronic kidney disease
History of malignancy in the last five years
Active drug or alcohol dependence or abuse (excluding tobacco use) within the 12 months prior to Screening
Any known allergies to iron products
Previous intolerance to oral ferric citrate
Psychiatric disorder that interferes with the subject's ability to comply with the study protocol
Planned surgery or hospitalization during the trial
Any other medical condition that, in the opinion of the PI, renders the subject unable to or unlikely to complete the trial or that would interfere with optimal participation in the trial or produce significant risk to the subject
Intervention: Folfirinox Regimen
Trial phase: Phase 2
SMILES: CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(O)CC.Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1)CN2.O=C([O-])C(=O)[O-].O=c1[nH]cc(F)c(=O)[nH]1.[NH-]C1CCCCC1[NH-].[Pt+4]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Folfirinox

Oxaliplatin 85 mg/m² for over 2 hours,
Leucovorin 400n mg/m² for over 2 hours,
Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion
Fluorouracil 400 mg/m² as a fast infusion over 15 minutes
Fluorouracil 2400 mg/m² as a slow infusion over 46 hours

SBRT 5 treatments of stereotactic body radiation therapy (SBRT) over the course of two weeks with a minimum of 36 hours in between each treatment.

Folfirinox: o Oxaliplatin 85 mg/m² for over 2 hours,

Leucovorin 400n mg/m² for over 2 hours,
Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion
Fluorouracil 400 mg/m² as a fast infusion over 15 minutes
Fluorouracil 2400 mg/m² as a slow infusion over 46 hours

Stereotactic Body Radiation Therapy: 5 treatments of stereotactic ablative radiotherapy (SABR) over the course of two weeks with a minimum of 36 hours in between each treatment.
Eligibility criteria:
Inclusion Criteria:

Age >/= 18 years
ECOG performance status 0-1
Pathologic or clinical diagnosis of a new pancreatic adenocarcinoma. A reasonable attempt should be made to make a pathologic diagnosis of malignancy.

Imaging as follows:

CT scan of the chest, abdomen and pelvis with IV and oral contrast within 8 weeks of registration
Whole body PET scan within 8 weeks of registration
Evaluation by a surgical oncologist to determine non-resectability
Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential.

CBC/differential obtained within 14 days prior to registration with adequate bone marrow function as follows:

ANC > 1,500 cell/mm3
Platelets > 100,000 cells/mm3
Hemoglobin > 8.0 g/dl (transfusion to obtain this value is permissible)

Additional labs within 14 days prior to registration

CA 19-9
Creatinine <2mg/dl
Bilirubin <2mg/dl
AST and ALT < 2.5 x ULN
Patients must provide study specific informed consent prior to study entry.

Exclusion Criteria:

Metastatic disease as defined by the multi-disciplinary team
Prior anti-cancer therapy for a pancreatic tumor
Prior malignancy within the last 3 years.
Pregnant women or lactating women
Acquired Immune Deficiency Syndrome (AIDS) based on CDC criteria. However HIV testing is not manditory for this protocol
Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
Intervention: Promethazine
Trial phase: Phase 2
ATC code: D04AA10 | R06AD02 | R06AD52 | V03AB05
SMILES: CC(CN1c2ccccc2Sc2ccccc21)N(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 2
Group description: Promethazine 12.5 mg P.O. t.i.d. for 4 weeks

Promethazine
Eligibility criteria:
Inclusion Criteria:

adult patients 18-65 years of age
clinical diagnosis of diabetic gastroparesis.
EGD without evidence of gastric outlet obstruction within the past five years
gastric emptying scintigraphy test demonstrating >10% solid food retention at 4 hours within the past three years.

Exclusion Criteria:

the inability or unwillingness to provide informed consent
currently pregnant or breast feeding
prior placement of a gastric stimulator
pyloric botulinum toxin injection within the past 12 months
prior gastric surgery
history of a connective tissue disorder
use of narcotic medication within the past four weeks
hemoglobin A1C >12 mg/dL within the past 3 months
current or recent (within past 4 weeks) use of promethazine, metoclopramide or domperidone
hypersensitivity or prior adverse reaction to promethazine
concomitant use of phenothiazines (i.e. prochlorperazine, chlorpromazine) or other agents likely to increase extrapyramidal reactions
concomitant use of tiotropium or ipratropium
narrow angle glaucoma
urinary retention
Parkinson's disease
significant psychiatric disease
history of seizure.